tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2014-1-19-31tumors-3Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL REPORTSТРОЙНОЙ НЕГАТИВНЫЙ РАК МОЛОЧНОЙ ЖЕЛЕЗЫ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ И НЕ СОВСЕМ ОБЫЧНЫЙ СЛУЧАЙ ЛЕЧЕНИЯTriple negative breast cancer: current status of the problem and unusual case of treatmentМуфазаловФ. Ф.MufazalovF. F.

Заместитель главного врача по радиологии, доктор медицинских наук,профессор, главный радиолог МЗ Республики Башкортостан, вице-президент Российской Ассоциации терапевтических радиационных онкологов (РАТРО).

ШариповаН. С.SharipovaN. S.sh-nailya27@mail.ruГБУЗ «Республиканский клинический онкологический диспансер» МЗ республики Башкортостан, г. УфаRussian Federation201419052015011931Copyright © Муфазалов Ф.Ф., Шарипова Н.С., 20152015Муфазалов Ф.Ф., Шарипова Н.С.Mufazalov F.F., Sharipova N.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/3

В статье представлен обзор литературных данных о клинических исследованиях, посвященных лечению тройного негативного рака молочной железы (ТНРМЖ), рассматривается активность существующих таргетных и химиопрепаратов. Описан не совсем обычный случай клинического течения и лечения ТНРМЖ.

The article presents a review of clinical trials of treatment the triple negative breast cancer (TNBC). It considered the activity of existing target agents and chemotherapy. Described is not an ordinary case of the clinical course and treatment of TNBC.

тройной негативный рак молочной железыклинический случайtriple negative breast cancerclinical case reportReferencesСемиглазов В. Ф. Стратегические и практические подходы к решению проблемы рака молочной железы. — М. — RUSSCO. — 2013. — № 4. — С. 1–3.Семиглазов В. Ф. Стратегические и практические подходы к решению проблемы рака молочной железы. — М. — RUSSCO. — 2013. — № 4. — С. 1–3.Коваленко Е. И. Адъювантная терапия тройного негативного рака молочной железы // Видеоматериалы Большой конференции RUSSCO «Рак молочной железы», Москва, 22–24 января 2014 г. — http://www.rosoncoweb.ru/events/2014/01/22/archive/Коваленко Е. И. Адъювантная терапия тройного негативного рака молочной железы // Видеоматериалы Большой конференции RUSSCO «Рак молочной железы», Москва, 22–24 января 2014 г. — http://www.rosoncoweb.ru/events/2014/01/22/archive/Жукова Л. Г. Современные возможности терапии метастатического рака молочной железы с тройным негативным фенотипом // Материалы Большой конференции RUSSCO «Рак молочной железы», Москва, 22–24 января 2014 г. — М., 2014. — С. 235–241.Жукова Л. Г. Современные возможности терапии метастатического рака молочной железы с тройным негативным фенотипом // Материалы Большой конференции RUSSCO «Рак молочной железы», Москва, 22–24 января 2014 г. — М., 2014. — С. 235–241.Haffty B. G., Yang Q., Reiss M. et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer // J ClinOncol. — 2006; 24: 5652–5657.Haffty B. G., Yang Q., Reiss M. et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer // J ClinOncol. — 2006; 24: 5652–5657.Lehmann B. D., Bauer J. A., Chen X. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies // J Clin Invest. — 2011; 121: 2750–2767.Lehmann B. D., Bauer J. A., Chen X. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies // J Clin Invest. — 2011; 121: 2750–2767.Gonzalez-Angulo A.M., Timms K. M., Liu S. et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer // Clin Cancer Res. — 2011; 17: 1082–1089.Gonzalez-Angulo A.M., Timms K. M., Liu S. et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer // Clin Cancer Res. — 2011; 17: 1082–1089.Byrski T., Huzarski T., Dent R. et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients // Breast Cancer Res Treat. — 2009; 115: 359–363.Byrski T., Huzarski T., Dent R. et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients // Breast Cancer Res Treat. — 2009; 115: 359–363.Bhattacharyya G. S., Basu S., Agarwal V. et al. Single institute phase II study of weekly cisplatinum and metronomic dosing of cyclophosphamide and methotrexate in second line metastatic breast cancer triple-negative // Eur J Cancer. — 2009.Bhattacharyya G. S., Basu S., Agarwal V. et al. Single institute phase II study of weekly cisplatinum and metronomic dosing of cyclophosphamide and methotrexate in second line metastatic breast cancer triple-negative // Eur J Cancer. — 2009.Carey L. A., Rugo H. S., Marcom P. K. et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer // J ClinOncol. — 2008; 26 (Abstr 1009, presented data — ASCO Annual Meeting 2008).Carey L. A., Rugo H. S., Marcom P. K. et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer // J ClinOncol. — 2008; 26 (Abstr 1009, presented data — ASCO Annual Meeting 2008).Frasci G., Comella P., Rinaldo M. et al. Preoperative weekly cisplatin–epirubicin–paclitaxel with G-CSF support in triple-negative large operable breast cancer // AnnOncol. — 2009; 20: 1185–1192.Frasci G., Comella P., Rinaldo M. et al. Preoperative weekly cisplatin–epirubicin–paclitaxel with G-CSF support in triple-negative large operable breast cancer // AnnOncol. — 2009; 20: 1185–1192.O’Shaughnessy J., Osborne C., Pippen J. E. et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer // N Engl J Med. — 2011; 364: 205–214.O’Shaughnessy J., Osborne C., Pippen J. E. et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer // N Engl J Med. — 2011; 364: 205–214.O’Shaughnessy J., Schwartzberg L. S., Danso M. A. et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/ carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) // J ClinOncol. — 2011; 29: (Abstr 1007, presented data — ASCO Annual Meeting 2011).O’Shaughnessy J., Schwartzberg L. S., Danso M. A. et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/ carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) // J ClinOncol. — 2011; 29: (Abstr 1007, presented data — ASCO Annual Meeting 2011).Linderholm B. K., Hellborg H., Johansson U. et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer // Ann Oncol. — 2009; 20:1639–1646.Linderholm B. K., Hellborg H., Johansson U. et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer // Ann Oncol. — 2009; 20:1639–1646.O’Shaughnessy J., Dieras V., Glaspy J. et al. Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC) // Cancer Res. — 2009; 69: (Abstr 207, presented data — SABCS 2009).O’Shaughnessy J., Dieras V., Glaspy J. et al. Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC) // Cancer Res. — 2009; 69: (Abstr 207, presented data — SABCS 2009).Brufsky A., Valero V., Tiangco B. et al. Impact of bevacizumab (BEV) on ef ficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): analysis of RIBBON-2 // J ClinOncol. — 2011; 29: (Abstr 1010, presented data — ASCO Annual Meeting 2011).Brufsky A., Valero V., Tiangco B. et al. Impact of bevacizumab (BEV) on ef ficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): analysis of RIBBON-2 // J ClinOncol. — 2011; 29: (Abstr 1010, presented data — ASCO Annual Meeting 2011).VonMinckwitz G. Eidtmann H., Rezai M. et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer // N Engl J Med. — 2012; 366:299–309.VonMinckwitz G. Eidtmann H., Rezai M. et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer // N Engl J Med. — 2012; 366:299–309.Bear H. D., Tang G., Rastogi P. et al. The ef fect on pCR of bevacizumab and/ or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40 // J ClinOncol. — 2011; 29: (Abstr LBA 1005, presented data — ASCO Annual Meeting 2011).Bear H. D., Tang G., Rastogi P. et al. The ef fect on pCR of bevacizumab and/ or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40 // J ClinOncol. — 2011; 29: (Abstr LBA 1005, presented data — ASCO Annual Meeting 2011).Cameron D., Brown J., Dent R. et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial // J The Lancet Oncol. — 2013; 14:933–942.Cameron D., Brown J., Dent R. et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial // J The Lancet Oncol. — 2013; 14:933–942.Curigliano G., Pivot X., Cortes J. et al. A randomized phase II study of sunitinib vs. standard of care for patients with previously treated advanced triple-negative breast cancer // Cancer Res. — 2010; 70: (Abstr P6–12–02, presented data — SABCS 2010).Curigliano G., Pivot X., Cortes J. et al. A randomized phase II study of sunitinib vs. standard of care for patients with previously treated advanced triple-negative breast cancer // Cancer Res. — 2010; 70: (Abstr P6–12–02, presented data — SABCS 2010).Wildiers H., Fontaine C., Vuylsteke P. et al. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer // Breast Cancer Res Treat. — 2010; 123: 463–469.Wildiers H., Fontaine C., Vuylsteke P. et al. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer // Breast Cancer Res Treat. — 2010; 123: 463–469.Burstein H. J., Elias A. D., Rugo H. S. et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane // J ClinOncol. — 2008; 26: 1810–1816.Burstein H. J., Elias A. D., Rugo H. S. et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane // J ClinOncol. — 2008; 26: 1810–1816.Moreno-Aspitia A., Morton R. F., Hillman D. W. et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer T reatment Group and Mayo Clinic Trial N0336 // J ClinOncol. — 2009; 27: 11–15.Moreno-Aspitia A., Morton R. F., Hillman D. W. et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer T reatment Group and Mayo Clinic Trial N0336 // J ClinOncol. — 2009; 27: 11–15.Bianchi G., Loibl S., Zamagni C. et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer // Anticancer Drugs. — 2009; 20:616–624.Bianchi G., Loibl S., Zamagni C. et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer // Anticancer Drugs. — 2009; 20:616–624.Gomez P., Roche H., Costa F. et al. Overall survival data from SOLTI-0701: a multinational, double-blind, placebo-controlled, randomized phase2b study evaluating the oral combination of sorafenib and apecitabine in patients with locally advanced or metastatic HER2-negative breast cancer // Cancer Res. — 2010;70: (Abstr P2–16–01, presented data — SABCS 2010).Gomez P., Roche H., Costa F. et al. Overall survival data from SOLTI-0701: a multinational, double-blind, placebo-controlled, randomized phase2b study evaluating the oral combination of sorafenib and apecitabine in patients with locally advanced or metastatic HER2-negative breast cancer // Cancer Res. — 2010;70: (Abstr P2–16–01, presented data — SABCS 2010).Hudis C., Tauer K. W., Hermann R. C. et al. Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously reated with bevacizumab (BEV) // J ClinOncol. — 2011; 29: (Abstr 1009, presented data — ASCO Annual Meeting 2011).Hudis C., Tauer K. W., Hermann R. C. et al. Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously reated with bevacizumab (BEV) // J ClinOncol. — 2011; 29: (Abstr 1009, presented data — ASCO Annual Meeting 2011).Viale G., Rotmensz N., Maisonneuve P. et al. Invasive ductal carcinoma of the breast with the «triple-negative» phenotype: prognostic implications of EGFR immunoreactivit y // Breast Cancer Res Treat. — 2009; 116: 317–328.Viale G., Rotmensz N., Maisonneuve P. et al. Invasive ductal carcinoma of the breast with the «triple-negative» phenotype: prognostic implications of EGFR immunoreactivit y // Breast Cancer Res Treat. — 2009; 116: 317–328.Rakha E. A., El-Sayed M.E., Green A. R. et al. Prognostic markers in triple-negative breast cancer // Cancer. — 2007; 109: 25–32.Rakha E. A., El-Sayed M.E., Green A. R. et al. Prognostic markers in triple-negative breast cancer // Cancer. — 2007; 109: 25–32.Baselga J., Stemmer S., Pego A. et al. Cetuximab + cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial // Cancer Res. — 2010; 70: (Abstr PD01–01, presented data — SABCS 2010).Baselga J., Stemmer S., Pego A. et al. Cetuximab + cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial // Cancer Res. — 2010; 70: (Abstr PD01–01, presented data — SABCS 2010).O’Shaughnessy J., Weckstein D., Vukelja S. et al. Preliminary results of a randomized phase II study of weekly irinotecan/ carboplatin with or without cetuximab in patients with metastatic breast cancer // Breast Cancer Res Treat 2007; 106: S32 (Abstr 308, presented data — SABCS 2007).O’Shaughnessy J., Weckstein D., Vukelja S. et al. Preliminary results of a randomized phase II study of weekly irinotecan/ carboplatin with or without cetuximab in patients with metastatic breast cancer // Breast Cancer Res Treat 2007; 106: S32 (Abstr 308, presented data — SABCS 2007).Sharma P., Khan Q. J., Kimler B. F. et al. Results of a phase II study of neoadjuvant platinum/ taxane based chemotherapy and erlotinib for triple negative breast cancer // Cancer Res. — 2010; 70: (Abstr P1–11–07, presented data — SABCS 2010).Sharma P., Khan Q. J., Kimler B. F. et al. Results of a phase II study of neoadjuvant platinum/ taxane based chemotherapy and erlotinib for triple negative breast cancer // Cancer Res. — 2010; 70: (Abstr P1–11–07, presented data — SABCS 2010).Finn R. S., Press M. F., Dering J. et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitax el with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer // J ClinOncol. — 2009; 27: 3908–3915.Finn R. S., Press M. F., Dering J. et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitax el with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer // J ClinOncol. — 2009; 27: 3908–3915.Rakha E. A., El-Sayed M.E., Green A. R. et al. Prognostic markers in triple-negative breast cancer // Cancer. — 2007; 109: 25–32.Rakha E. A., El-Sayed M.E., Green A. R. et al. Prognostic markers in triple-negative breast cancer // Cancer. — 2007; 109: 25–32.Noh W. C., Mondesire W. H., Peng J. et al. Determinants of rapamycin sensitivit y in breast cancer cells // Clin Cancer Res. — 2004; 10: 1013–1023.Noh W. C., Mondesire W. H., Peng J. et al. Determinants of rapamycin sensitivit y in breast cancer cells // Clin Cancer Res. — 2004; 10: 1013–1023.Yu K., Toral-Barza L., Discafani C. et al. mTOR, a novel target in breast cancer: the ef fect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer // EndocrRelat Cancer. — 2001; 8: 249–258.Yu K., Toral-Barza L., Discafani C. et al. mTOR, a novel target in breast cancer: the ef fect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer // EndocrRelat Cancer. — 2001; 8: 249–258.Mayer I., Burris H., Bendell J. et al. A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer // Cancer Res. — 2009; 69: (Abstr 3093, presented data — SABCS 2009).Mayer I., Burris H., Bendell J. et al. A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer // Cancer Res. — 2009; 69: (Abstr 3093, presented data — SABCS 2009).Andre F., Campone M., O’Regan R. et al. Phase I study of everolimus plus weekly paclitax el and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab // J ClinOncol. — 2010; 28: 5110–5115.Andre F., Campone M., O’Regan R. et al. Phase I study of everolimus plus weekly paclitax el and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab // J ClinOncol. — 2010; 28: 5110–5115.Gonzalez-Angulo A.M., Green M. C., Murray J. L. et al. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC) // J ClinOncol. — 2011; 29: (Abstr 1016, presented data — ASCO Annual Meeting 2011).Gonzalez-Angulo A.M., Green M. C., Murray J. L. et al. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC) // J ClinOncol. — 2011; 29: (Abstr 1016, presented data — ASCO Annual Meeting 2011).

The authors declare that there are no conflicts of interest present.